NCT01242111
MPS IVA, Morquio A Syndrome, Mucopolysaccharidosis IVA, MPS IV A
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
This multicenter, open-label extension study is designed to assess long-term efficacy and safety of 2.0 milligrams (mg)/kilogram(kg)/week of BMN 110 in patients diagnosed with Mucopolysaccharidosis IVA (MPS IVA). Patients with MPS IVA, who enrolled in a prior BioMarin sponsored clinical study of BMN 110 (NCT00884949; Study Identification Number MOR-002), were eligible to enroll in this study (except patients who enrolled in NCT01275066; Study Identification Number MOR-004).
All
Any
No
BMN 110
Phase 1/Phase 2
Interventional
20
2010-11
2015-09-30
Birmingham, , United Kingdom
Dumfries, , United Kingdom
London, , United Kingdom
Manchester, , United Kingdom
*required fields
"*" indicates required fields